Edesa Biotech Company Insiders
EDSA Stock | USD 2.11 0.09 4.09% |
Edesa Biotech employs about 16 people. The company is managed by 7 executives with a total tenure of roughly 38 years, averaging almost 5.0 years of service per executive, having 2.29 employees per reported executive. Analysis of Edesa Biotech's management performance can provide insight into the company performance.
Edesa |
Edesa Biotech's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Edesa Biotech's future performance. Based on our forecasts, it is anticipated that Edesa will maintain a workforce of about 16 employees by December 2024.Edesa Biotech Management Team Effectiveness
The company has return on total asset (ROA) of (0.7152) % which means that it has lost $0.7152 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2929) %, meaning that it created substantial loss on money invested by shareholders. Edesa Biotech's management efficiency ratios could be used to measure how well Edesa Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.61. In addition to that, Return On Capital Employed is expected to decline to -0.46. At present, Edesa Biotech's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 209.5 K, whereas Total Assets are forecasted to decline to about 8.7 M.The current year's Common Stock Shares Outstanding is expected to grow to about 3.5 M, whereas Net Loss is projected to grow to (15 M).
Edesa Biotech Workforce Comparison
Edesa Biotech is one of the top stocks in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 71.0. Edesa Biotech totals roughly 16.0 in number of employees claiming about 23% of equities under Health Care industry.
Edesa Biotech Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edesa Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edesa Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Edesa Biotech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2021-03-01 | 4.0 | 4 | 1 | 16,000 | 6,165 |
2020-12-01 | 2.25 | 18 | 8 | 363,772 | 19,410 |
2019-09-01 | 12.0 | 12 | 1 | 277,205 | 1,809 |
2019-03-01 | 6.0 | 6 | 1 | 2,142 | 4,000 |
2018-03-01 | 1.8333 | 11 | 6 | 125,000 | 36,666 |
2017-03-01 | 7.0 | 7 | 1 | 25,000 | 40,188 |
2016-12-01 | 7.0 | 7 | 1 | 25,000 | 1,250 |
2015-12-01 | 1.3333 | 4 | 3 | 44,000 | 309,000 |
2014-12-01 | 1.0 | 2 | 2 | 102,500 | 28,000 |
Edesa Biotech Notable Stakeholders
An Edesa Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Edesa Biotech often face trade-offs trying to please all of them. Edesa Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Edesa Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
CPA CPA | Chief Officer | Profile | |
BA CPA | Chief Officer | Profile | |
Dr MBA | President | Profile | |
Gary Koppenjan | VP Communications | Profile | |
MD FRCPC | Company CEO | Profile | |
Rajan Puri | VP Manufacturing | Profile | |
BA CA | Chief Officer | Profile |
About Edesa Biotech Management Performance
The success or failure of an entity such as Edesa Biotech often depends on how effective the management is. Edesa Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Edesa management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Edesa management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.58) | (0.61) | |
Return On Capital Employed | (0.44) | (0.46) | |
Return On Assets | (0.58) | (0.61) | |
Return On Equity | (1.10) | (1.15) |
Please note, the presentation of Edesa Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Edesa Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Edesa Biotech's management manipulating its earnings.
Edesa Biotech Workforce Analysis
Traditionally, organizations such as Edesa Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Edesa Biotech within its industry.Edesa Biotech Manpower Efficiency
Return on Edesa Biotech Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 523.4K | |
Net Loss Per Executive | 1.2M | |
Working Capital Per Employee | 288.4K | |
Working Capital Per Executive | 659.3K |
Complementary Tools for Edesa Stock analysis
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Money Managers Screen money managers from public funds and ETFs managed around the world |